Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy
We investigated whether myocardial biopsy analysis for inflammation and viruses correlates with outcome in dilated cardiomyopathy. Myocardial biopsies of 82 patients were analyzed for HLAI, HLAII, CD54, CD2, CD68 and entero-/adenovirus. Ejection fraction was determined by left ventriculography. NYHA...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2005-09, Vol.104 (1), p.92-100 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100 |
|---|---|
| container_issue | 1 |
| container_start_page | 92 |
| container_title | International journal of cardiology |
| container_volume | 104 |
| creator | Zimmermann, Oliver Kochs, Matthias Zwaka, Thomas Paul Kaya, Ziya Lepper, Philipp Moritz Bienek-Ziolkowski, Magdalena Hoher, Martin Hombach, Vinzenz Torzewski, Jan |
| description | We investigated whether myocardial biopsy analysis for inflammation and viruses correlates with outcome in dilated cardiomyopathy.
Myocardial biopsies of 82 patients were analyzed for HLAI, HLAII, CD54, CD2, CD68 and entero-/adenovirus. Ejection fraction was determined by left ventriculography. NYHA classification, electrocardiogram (ECG) and echocardiography were analyzed at first admission and for follow up. Patients were attributed to three groups: (A) no inflammation/no virus (B) inflammation/no virus (C) virus with/without inflammation. Patients not responding to conventional treatment of heart failure received interferon β1b (group C) or prednisolone (group B). Median follow up was 7 months (group A), 11 months (group B) and 14.5 months (group C).
Thirty nine patients (48%) belonged to group A, 33 patients (40%) to group B, 10 patients (12%) to group C. Only enterovirus was detected. Ejection fraction at admission was worse for group B compared to group A (
p
=
0.003). Groups A and B improved for echochardiography and NYHA (
p
≤
0.001). Group C improved for echocardiography only (
p
=
0.031). Group B showed a better outcome for echocardiography (
p
=
0.014) and NYHA (
p
=
0.023) than group A.
Inflammatory cardiomyopathy shows the best outcome. Antiinflammatory or antiviral treatment may be an option in patients not responding to conventional therapy. |
| doi_str_mv | 10.1016/j.ijcard.2005.02.052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68551486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527305005097</els_id><sourcerecordid>68551486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-965d562276ea2ebe80cf5480d5b700f5daea1ecf8c8196ff833f7297a2309b883</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhoNY7G31H4hkY3cznmQmH7MRpFQrVLrRnRAy-aC5zEyuSa5l_r0Z7oXuXJ1w8rwvhweh9wRaAoR_2rdhb3SyLQVgLdAWGH2FdkSKviGC9a_RrmKiYVR0l-gq5z0A9MMg36BLwkknGOE79PvHGreWoCc8hnjIKx51dhabSeccfDC6hLhgvVhcktNldkvBYcGHuq_PjJ9DecI2TLpsqa0qzmus30_rW3Th9ZTdu_O8Rr--3v28vW8eHr99v_3y0JhugNIMnFnGKRXcaepGJ8F41kuwbBQAnlntNHHGSyPJwL2XXecFHYSmHQyjlN01ujn1HlL8c3S5qDlk46ZJLy4es-KSMdJLXsH-BJoUc07Oq0MKs06rIqA2q2qvTlbVZlUBVdVqjX049x_H2dmX0FljBT6eAZ2NnnzSiwn5hRMgJAVWuc8nzlUbf4NLKptq0TgbkjNF2Rj-f8k_7TaY5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68551486</pqid></control><display><type>article</type><title>Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Zimmermann, Oliver ; Kochs, Matthias ; Zwaka, Thomas Paul ; Kaya, Ziya ; Lepper, Philipp Moritz ; Bienek-Ziolkowski, Magdalena ; Hoher, Martin ; Hombach, Vinzenz ; Torzewski, Jan</creator><creatorcontrib>Zimmermann, Oliver ; Kochs, Matthias ; Zwaka, Thomas Paul ; Kaya, Ziya ; Lepper, Philipp Moritz ; Bienek-Ziolkowski, Magdalena ; Hoher, Martin ; Hombach, Vinzenz ; Torzewski, Jan</creatorcontrib><description>We investigated whether myocardial biopsy analysis for inflammation and viruses correlates with outcome in dilated cardiomyopathy.
Myocardial biopsies of 82 patients were analyzed for HLAI, HLAII, CD54, CD2, CD68 and entero-/adenovirus. Ejection fraction was determined by left ventriculography. NYHA classification, electrocardiogram (ECG) and echocardiography were analyzed at first admission and for follow up. Patients were attributed to three groups: (A) no inflammation/no virus (B) inflammation/no virus (C) virus with/without inflammation. Patients not responding to conventional treatment of heart failure received interferon β1b (group C) or prednisolone (group B). Median follow up was 7 months (group A), 11 months (group B) and 14.5 months (group C).
Thirty nine patients (48%) belonged to group A, 33 patients (40%) to group B, 10 patients (12%) to group C. Only enterovirus was detected. Ejection fraction at admission was worse for group B compared to group A (
p
=
0.003). Groups A and B improved for echochardiography and NYHA (
p
≤
0.001). Group C improved for echocardiography only (
p
=
0.031). Group B showed a better outcome for echocardiography (
p
=
0.014) and NYHA (
p
=
0.023) than group A.
Inflammatory cardiomyopathy shows the best outcome. Antiinflammatory or antiviral treatment may be an option in patients not responding to conventional therapy.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2005.02.052</identifier><identifier>PMID: 16137516</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adult ; Aged ; Anti-Inflammatory Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Biopsy ; Cardiology. Vascular system ; Cardiomyopathy, Dilated - metabolism ; Cardiomyopathy, Dilated - pathology ; Cardiomyopathy, Dilated - therapy ; CD2 Antigens - drug effects ; CD2 Antigens - metabolism ; Dilated cardiomyopathy ; Echocardiography ; Electrocardiography ; Female ; Follow-Up Studies ; Germany ; Heart ; Heart Failure - pathology ; Heart Failure - therapy ; Humans ; Inflammation Mediators - metabolism ; Interferon beta-1b ; Interferon β1b ; Interferon-beta - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Myocarditis - pathology ; Myocarditis - therapy ; Myocarditis. Cardiomyopathies ; Myocardium - pathology ; Outcome ; Pharmacology. Drug treatments ; Prednisolone ; Prednisolone - therapeutic use ; Retrospective Studies ; Severity of Illness Index ; Stroke Volume - drug effects</subject><ispartof>International journal of cardiology, 2005-09, Vol.104 (1), p.92-100</ispartof><rights>2005 Elsevier Ireland Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-965d562276ea2ebe80cf5480d5b700f5daea1ecf8c8196ff833f7297a2309b883</citedby><cites>FETCH-LOGICAL-c390t-965d562276ea2ebe80cf5480d5b700f5daea1ecf8c8196ff833f7297a2309b883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2005.02.052$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17078205$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16137516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimmermann, Oliver</creatorcontrib><creatorcontrib>Kochs, Matthias</creatorcontrib><creatorcontrib>Zwaka, Thomas Paul</creatorcontrib><creatorcontrib>Kaya, Ziya</creatorcontrib><creatorcontrib>Lepper, Philipp Moritz</creatorcontrib><creatorcontrib>Bienek-Ziolkowski, Magdalena</creatorcontrib><creatorcontrib>Hoher, Martin</creatorcontrib><creatorcontrib>Hombach, Vinzenz</creatorcontrib><creatorcontrib>Torzewski, Jan</creatorcontrib><title>Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>We investigated whether myocardial biopsy analysis for inflammation and viruses correlates with outcome in dilated cardiomyopathy.
Myocardial biopsies of 82 patients were analyzed for HLAI, HLAII, CD54, CD2, CD68 and entero-/adenovirus. Ejection fraction was determined by left ventriculography. NYHA classification, electrocardiogram (ECG) and echocardiography were analyzed at first admission and for follow up. Patients were attributed to three groups: (A) no inflammation/no virus (B) inflammation/no virus (C) virus with/without inflammation. Patients not responding to conventional treatment of heart failure received interferon β1b (group C) or prednisolone (group B). Median follow up was 7 months (group A), 11 months (group B) and 14.5 months (group C).
Thirty nine patients (48%) belonged to group A, 33 patients (40%) to group B, 10 patients (12%) to group C. Only enterovirus was detected. Ejection fraction at admission was worse for group B compared to group A (
p
=
0.003). Groups A and B improved for echochardiography and NYHA (
p
≤
0.001). Group C improved for echocardiography only (
p
=
0.031). Group B showed a better outcome for echocardiography (
p
=
0.014) and NYHA (
p
=
0.023) than group A.
Inflammatory cardiomyopathy shows the best outcome. Antiinflammatory or antiviral treatment may be an option in patients not responding to conventional therapy.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy, Dilated - metabolism</subject><subject>Cardiomyopathy, Dilated - pathology</subject><subject>Cardiomyopathy, Dilated - therapy</subject><subject>CD2 Antigens - drug effects</subject><subject>CD2 Antigens - metabolism</subject><subject>Dilated cardiomyopathy</subject><subject>Echocardiography</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Germany</subject><subject>Heart</subject><subject>Heart Failure - pathology</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Inflammation Mediators - metabolism</subject><subject>Interferon beta-1b</subject><subject>Interferon β1b</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocarditis - pathology</subject><subject>Myocarditis - therapy</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Myocardium - pathology</subject><subject>Outcome</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone</subject><subject>Prednisolone - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Stroke Volume - drug effects</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhoNY7G31H4hkY3cznmQmH7MRpFQrVLrRnRAy-aC5zEyuSa5l_r0Z7oXuXJ1w8rwvhweh9wRaAoR_2rdhb3SyLQVgLdAWGH2FdkSKviGC9a_RrmKiYVR0l-gq5z0A9MMg36BLwkknGOE79PvHGreWoCc8hnjIKx51dhabSeccfDC6hLhgvVhcktNldkvBYcGHuq_PjJ9DecI2TLpsqa0qzmus30_rW3Th9ZTdu_O8Rr--3v28vW8eHr99v_3y0JhugNIMnFnGKRXcaepGJ8F41kuwbBQAnlntNHHGSyPJwL2XXecFHYSmHQyjlN01ujn1HlL8c3S5qDlk46ZJLy4es-KSMdJLXsH-BJoUc07Oq0MKs06rIqA2q2qvTlbVZlUBVdVqjX049x_H2dmX0FljBT6eAZ2NnnzSiwn5hRMgJAVWuc8nzlUbf4NLKptq0TgbkjNF2Rj-f8k_7TaY5A</recordid><startdate>20050915</startdate><enddate>20050915</enddate><creator>Zimmermann, Oliver</creator><creator>Kochs, Matthias</creator><creator>Zwaka, Thomas Paul</creator><creator>Kaya, Ziya</creator><creator>Lepper, Philipp Moritz</creator><creator>Bienek-Ziolkowski, Magdalena</creator><creator>Hoher, Martin</creator><creator>Hombach, Vinzenz</creator><creator>Torzewski, Jan</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050915</creationdate><title>Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy</title><author>Zimmermann, Oliver ; Kochs, Matthias ; Zwaka, Thomas Paul ; Kaya, Ziya ; Lepper, Philipp Moritz ; Bienek-Ziolkowski, Magdalena ; Hoher, Martin ; Hombach, Vinzenz ; Torzewski, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-965d562276ea2ebe80cf5480d5b700f5daea1ecf8c8196ff833f7297a2309b883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy, Dilated - metabolism</topic><topic>Cardiomyopathy, Dilated - pathology</topic><topic>Cardiomyopathy, Dilated - therapy</topic><topic>CD2 Antigens - drug effects</topic><topic>CD2 Antigens - metabolism</topic><topic>Dilated cardiomyopathy</topic><topic>Echocardiography</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Germany</topic><topic>Heart</topic><topic>Heart Failure - pathology</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Inflammation Mediators - metabolism</topic><topic>Interferon beta-1b</topic><topic>Interferon β1b</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocarditis - pathology</topic><topic>Myocarditis - therapy</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Myocardium - pathology</topic><topic>Outcome</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone</topic><topic>Prednisolone - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Stroke Volume - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimmermann, Oliver</creatorcontrib><creatorcontrib>Kochs, Matthias</creatorcontrib><creatorcontrib>Zwaka, Thomas Paul</creatorcontrib><creatorcontrib>Kaya, Ziya</creatorcontrib><creatorcontrib>Lepper, Philipp Moritz</creatorcontrib><creatorcontrib>Bienek-Ziolkowski, Magdalena</creatorcontrib><creatorcontrib>Hoher, Martin</creatorcontrib><creatorcontrib>Hombach, Vinzenz</creatorcontrib><creatorcontrib>Torzewski, Jan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zimmermann, Oliver</au><au>Kochs, Matthias</au><au>Zwaka, Thomas Paul</au><au>Kaya, Ziya</au><au>Lepper, Philipp Moritz</au><au>Bienek-Ziolkowski, Magdalena</au><au>Hoher, Martin</au><au>Hombach, Vinzenz</au><au>Torzewski, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2005-09-15</date><risdate>2005</risdate><volume>104</volume><issue>1</issue><spage>92</spage><epage>100</epage><pages>92-100</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>We investigated whether myocardial biopsy analysis for inflammation and viruses correlates with outcome in dilated cardiomyopathy.
Myocardial biopsies of 82 patients were analyzed for HLAI, HLAII, CD54, CD2, CD68 and entero-/adenovirus. Ejection fraction was determined by left ventriculography. NYHA classification, electrocardiogram (ECG) and echocardiography were analyzed at first admission and for follow up. Patients were attributed to three groups: (A) no inflammation/no virus (B) inflammation/no virus (C) virus with/without inflammation. Patients not responding to conventional treatment of heart failure received interferon β1b (group C) or prednisolone (group B). Median follow up was 7 months (group A), 11 months (group B) and 14.5 months (group C).
Thirty nine patients (48%) belonged to group A, 33 patients (40%) to group B, 10 patients (12%) to group C. Only enterovirus was detected. Ejection fraction at admission was worse for group B compared to group A (
p
=
0.003). Groups A and B improved for echochardiography and NYHA (
p
≤
0.001). Group C improved for echocardiography only (
p
=
0.031). Group B showed a better outcome for echocardiography (
p
=
0.014) and NYHA (
p
=
0.023) than group A.
Inflammatory cardiomyopathy shows the best outcome. Antiinflammatory or antiviral treatment may be an option in patients not responding to conventional therapy.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>16137516</pmid><doi>10.1016/j.ijcard.2005.02.052</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2005-09, Vol.104 (1), p.92-100 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68551486 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adjuvants, Immunologic - therapeutic use Adult Aged Anti-Inflammatory Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Biopsy Cardiology. Vascular system Cardiomyopathy, Dilated - metabolism Cardiomyopathy, Dilated - pathology Cardiomyopathy, Dilated - therapy CD2 Antigens - drug effects CD2 Antigens - metabolism Dilated cardiomyopathy Echocardiography Electrocardiography Female Follow-Up Studies Germany Heart Heart Failure - pathology Heart Failure - therapy Humans Inflammation Mediators - metabolism Interferon beta-1b Interferon β1b Interferon-beta - therapeutic use Male Medical sciences Middle Aged Myocarditis - pathology Myocarditis - therapy Myocarditis. Cardiomyopathies Myocardium - pathology Outcome Pharmacology. Drug treatments Prednisolone Prednisolone - therapeutic use Retrospective Studies Severity of Illness Index Stroke Volume - drug effects |
| title | Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T11%3A30%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myocardial%20biopsy%20based%20classification%20and%20treatment%20in%20patients%20with%20dilated%20cardiomyopathy&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Zimmermann,%20Oliver&rft.date=2005-09-15&rft.volume=104&rft.issue=1&rft.spage=92&rft.epage=100&rft.pages=92-100&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2005.02.052&rft_dat=%3Cproquest_cross%3E68551486%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68551486&rft_id=info:pmid/16137516&rft_els_id=S0167527305005097&rfr_iscdi=true |